newsfilter
← Latest News
PR Newswire·

Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that...